Illumina stock holds after a 2025 revenue rebound
Published on 07/23/2026 at 05:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Illumina stock (US4523271090) is anchored by $4.36 billion in 2025 revenue and a fourth-quarter revenue increase to $1.1 billion, even as the company reported a $1.1 billion net loss for the full year 2025. Those figures come from Illumina's 2025 results and frame the shares around execution rather than a single catalyst.
Revenue up 1.0% in 2025
Illumina reported 2025 revenue of $4.36 billion, up 1.0% from 2024, according to the company's annual results. Fourth-quarter revenue reached $1.1 billion, which was 3% above the prior-year quarter, showing that the top line was still moving in the right direction into year end.
The same report showed gross margin at 66.5% for 2025, compared with 67.1% in 2024. That narrower margin matters because Illumina is still trying to turn modest revenue growth into cleaner earnings power.
Losses still define the year
Net income for 2025 was a loss of $1.1 billion, while adjusted diluted EPS came in at $4.28 for the year, according to the annual figures. The contrast between the GAAP loss and adjusted earnings shows how much of the current narrative still depends on non-GAAP performance.
Operating cash flow for 2025 was $958 million, and free cash flow reached $835 million. For investors, that cash generation is the more useful counterweight to the loss line because it shows the business still produced cash after the weaker profit base.
2025 results and margin trend
Illumina's latest annual filing and results show why revenue growth and cash flow matter more than headline profit for now.
Sequencing sales drive the base
Illumina's sequencing systems remain the core product engine, and the company's 2025 report shows that the installed base and consumables activity still matter more than any single device launch. A 1.0% annual revenue rise does not look dramatic, but in a market that has reset after a period of tougher comparisons, it gives the business a steadier base.
Cash generation also supports that reading. Free cash flow of $835 million in 2025 gave Illumina room to keep funding operations while the company worked through lower profitability.
Shares and market value
Illumina stock was trading on Nasdaq, and the fact box below records the current venue and the latest market data that could be verified from the available materials. The most relevant investor lens remains whether the company can convert the 2025 revenue recovery into a cleaner margin profile in 2026.
Sequencing platforms and consumables
Illumina's products are built around sequencing platforms and consumables, which is why the annual revenue and margin figures matter more than broad company description. The 2025 numbers show a business that is still profitable on an adjusted basis, still cash generative, and still working through a loss on the GAAP line.
Nasdaq closing level
Illumina stock traded on Nasdaq, and the latest verified venue context in this article remains Nasdaq as the primary listing venue. The factual anchor for the year is the company's $4.36 billion 2025 revenue, 66.5% gross margin, and $835 million free cash flow, which together define the current setup better than any slogan.
Illumina Inc. at a glance
- Company: Illumina Inc.
- ISIN: US4523271090
- Ticker: NASDAQ: ILMN
- Trading venue: Nasdaq
- Sector / Industry: Health Care / Life Sciences Tools & Services
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
